丹参酮胶囊联合不同浓度5-氨基酮戊酸光动力疗法治疗囊肿性痤疮的临床疗效
Clinical efficacy of tanshinone capsules combined with varying concentrations of 5-ALA-PDT in the treatment of cystic acne.
作者信息
Yao Yan, Zuo Jing, Chen Li
机构信息
Department of Dermatology, Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210029, Jiangsu Province, China.
Department of Ophthalmology, Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210029, Jiangsu Province, China.
出版信息
Am J Transl Res. 2021 Sep 15;13(9):10816-10822. eCollection 2021.
OBJECTIVE
To investigate the clinical effectiveness and safety of tanshinone capsules combined with varying concentrations of 5-aminoketovaleric acid photodynamic therapy (5-ALA-PDT) in the treatment of cystic acne.
METHODS
A total of 97 patients with cystic acne treated in our hospital were enrolled in the study and divided into group A (n = 34, tanshinone capsules combined with 5% 5-ALA-PDT), group B (n = 31, tanshinone capsules combined with 7.5% 5-ALA-PDT), and group C (n = 32, tanshinone capsules combined with 10% 5-ALA-PDT). The number of skin lesions, the global acne grading system (GAGS) scores, the clinical effectiveness, the adverse reactions, and the recurrence rates were compared among the three groups.
RESULTS
The number of skin lesions and the GAGS scores were lower in all three groups at two weeks, one month, and three months of treatment (<0.05), and the numbers of skin lesions in groups B and C were significantly lower than the number in group A (<0.05). The clinical effectiveness in groups B and C was better than it was in group A (<0.05), and the overall effective rates in groups B and C (87.10% and 87.50%) were significantly higher than the overall effective rate in group A (41.18%) (<0.05). The adverse reaction rates in groups A and B (5.88% and 6.45%) were significantly lower than the adverse reaction rate in group C (25.00%) (<0.05), and the recurrence rate in group A (17.65%) was significantly higher than the recurrence rates in groups B and C (3.23% and 0.00%) (<0.05).
CONCLUSIONS
Tanshinone capsules combined with 7.5% 5-ALA-PDT showed the optimal clinical effectiveness and safety in the treatment of cystic acne.
目的
探讨丹参酮胶囊联合不同浓度的5-氨基酮戊酸光动力疗法（5-ALA-PDT）治疗囊肿性痤疮的临床疗效及安全性。
方法
选取我院收治的97例囊肿性痤疮患者纳入研究，分为A组（n = 34，丹参酮胶囊联合5% 5-ALA-PDT）、B组（n = 31，丹参酮胶囊联合7.5% 5-ALA-PDT）和C组（n = 32，丹参酮胶囊联合10% 5-ALA-PDT）。比较三组的皮肤损害数量、全球痤疮分级系统（GAGS）评分、临床疗效、不良反应及复发率。
结果
治疗2周、1个月和3个月时，三组的皮肤损害数量和GAGS评分均降低（<0.05），B组和C组的皮肤损害数量显著低于A组（<0.05）。B组和C组的临床疗效优于A组（<0.05），B组和C组的总有效率（87.10%和87.50%）显著高于A组的总有效率（41.18%）（<0.05）。A组和B组的不良反应发生率（5.88%和6.45%）显著低于C组的不良反应发生率（25.00%）（<0.05），A组的复发率（17.65%）显著高于B组和C组的复发率（3.23%和0.00%）（<0.05）。
结论
丹参酮胶囊联合7.5% 5-ALA-PDT治疗囊肿性痤疮显示出最佳的临床疗效和安全性。
Zotero 插件